PD-1 monoclonal antibody and lenvatinib

DRUG2 trials

Sponsors

Chen Xiaoping

Conditions

HCCRecurrence

Phase 4

Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma

RecruitingNCT06311929

Chen XiaopingHCC

Start: 2024-04-01End: 2028-12-31Target: 300Updated: 2024-05-07

Unknown Phase

VETC is an Effective Marker for Postoperative Adjuvant Immunotherapy

CompletedNCT06253364

Chen XiaopingHCC, Recurrence

Start: 2019-01-01End: 2024-01-31Updated: 2024-03-13